Literature DB >> 3570989

Studies on orally active cephalosporin esters.

K Fujimoto, S Ishihara, H Yanagisawa, J Ide, E Nakayama, H Nakao, S Sugawara, M Iwata.   

Abstract

The synthesis and the biological properties of orally active cephalosporin esters are described. 3-Methoxymethyl cephem derivatives having a 2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamide function at C-7 (1) showed good activity against a wide variety of bacteria including some beta-lactamase producing species. The prodrug type esters of 1 exhibited a good urinary recovery after oral administration to mice and 1-(isopropoxycarbonyloxy)ethyl ester (2a, CS-807) has been pre-clinically tested as an orally active cephem prodrug.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3570989     DOI： 10.7164/antibiotics.40.370

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  15 in total

Review 1.  Microbiological conclusions.

Authors:  R N Jones
Journal:  Drugs       Date:  1991       Impact factor: 9.546

2.  [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].

Authors:  A Bauernfeind; R Jungwirth; S Schweighart; M Theopold
Journal:  Infection       Date:  1990       Impact factor: 3.553

3.  In vitro activity of cefpodoxime against staphylococci in comparison to other cephalosporins.

Authors:  F Schumacher-Perdreau; B Jansen; G Peters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

4.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 5.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.

Authors:  R D Schaadt; B H Yagi; G E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 7.  Cefpodoxime proxetil in upper respiratory tract infections.

Authors:  E Bergogne-Berezin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

8.  Microbiological evaluation of cefpodoxime proxetil.

Authors:  B Wiedemann; E Luhmer; M T Zühlsdorf
Journal:  Drugs       Date:  1991       Impact factor: 9.546

9.  Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.